EVEREST-1 Trial Seeks to Bring HLA-A*02-directed CAR T to Patients With Solid Tumors

The upcoming phase 1/2 EVEREST-1 trial, where the novel CAR T-cell therapy A2B530 will be evaluated in patients with solid tumors, aims to push progress for one-and-done engineered therapies in this space.

Related Keywords

United States ,New York ,Dianem Simeone , ,Pancreatic Cancer Center ,Perlmutter Cancer Center ,Tmodt Cell ,News ,Everest 1 Trial ,Hlaa 02 Directed Cart Cell Therapy ,Solid Tumors ,